行气散结化瘀方联合还原型谷胱甘肽治疗原发性肝癌术后临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R735.7

基金项目:


Clinical Study on Xingqi Sanjie Huayu Prescription Combined with Reduced Glutathione for Patients After Surgery for Primary Liver Cancer
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察行气散结化瘀方联合还原型谷胱甘肽治疗原发性肝癌术后患者的临床疗效。方法:选取原发性肝癌患者80 例,按随机数字表法分为对照组和观察组各40 例。2 组均行腹腔镜肝癌切除术治疗,对照组于术后当天给予还原型谷胱甘肽口服,观察组在对照组基础上于术后当天给予行气散结化瘀方加减治疗。比较2 组治疗前后血清肿瘤标志物水平、免疫功能、肝功能、中医证候积分以及不良反应发生率。结果:治疗后,2 组甲胎蛋白(AFP)、糖类抗原199(CA199)、糖类抗原50(CA50)、白细胞介素-12(IL-12)、肿瘤坏死因子-α(TNF-α) 水平较治疗前降低(P<0.05),且观察组AFP、CA199、CA50、IL-12 及TNF-α 水平均低于对照组(P<0.05)。治疗后,2 组IL-2 水平较治疗前升高(P<0.05),且观察组IL-2 水平高于对照组(P<0.05)。治疗后,2 组谷草转氨酶(AST)、谷丙转氨酶(ALT) 水平以及中医证候积分较治疗前降低,白蛋白(Alb) 水平较治疗前升高(P<0.05);且观察组AST、ALT 水平以及中医证候积分低于对照组,Alb 水平高于对照组(P<0.05)。观察组恶心呕吐、皮疹、头晕、腹痛发生率均低于对照组,差异有统计学意义(P<0.05)。结论:行气散结化瘀方联合还原型谷胱甘肽治疗原发性肝癌术后患者可以有效改善患者临床症状,降低血清肿瘤标志物水平,增强免疫功能以及肝功能,降低不良反应发生率。

    Abstract:

    Abstract:Objective:To observe the clinical effect of the therapy of Xingqi Sanjie Huayu prescription combined with reduced glutathione on patients who had undergone surgery for primary liver cancer. Methods:A total of 80 patients with primary liver cancer were selected and divided into the control group and the observation group according to the random number table method, with 40 cases in each group. Both groups were treated with laparoscopic hepatectomy. The control group was additionally treated with reduced glutathione orally on the same day after surgery. The observation group was additionally treated with modified Xingqi Sanjie Huayu presription on the same day after surgery based on the treatment of the control group. Before and after treatment, the levels of serum tumor markers, immune function, liver function,Chinese medicine syndrome scores and incidence of adverse reactions were compared between the two groups. Results:After treatment,the levels of alpha-fetoprotein(AFP),carbohydrate antigen 199 (CA199), carbohydrate antigen 50(CA50), interleukin- 12(IL- 12) and tumor necrosis factor- α(TNF- α) in two groups were decreased when compared with those before treatment(P<0.05), and the above five levels in the observation group were lower than those in the control group(P<0.05). After treatment,the levels of IL- 2 in the two groups were increased when compared with those before treatment(P<0.05), and the level of IL- 12 in the observation group was higher than that in the control group(P<0.05). After treatment, the levels of aspartate aminotransferase(AST), alanine aminotransferase(ALT) and Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment,and the levels of albumin(Alb) were increased(P<0.05);the levels of AST,ALT and Chinese medicine syndrome scores in the observation group were lower than those in the control group,and the level of Alb in the observation group was higher(P<0.05). The incidence of nausea and vomiting, rash, dizziness and abdominal pain in the observation group was lower than that in the control group, the difference being significant(P<0.05). Conclusion: The therapy of Xingqi Sanjie Huayu prescription combined with reduced glutathione for patients who had undergone surgery for primary liver cancer can effectively improve the clinical symptoms, reduce the levels of serum tumor markers, enhance the immune function and liver function,and reduce the incidence of adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文

景霆.行气散结化瘀方联合还原型谷胱甘肽治疗原发性肝癌术后临床研究[J].新中医,2022,54(17):187-191

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-09-06
  • 出版日期: